Clinical trials highlight possible benefits of topical JAK inhibitors for hidradenitis suppurativa and vitiligo, suggesting new treatment options.
In recent years, Janus kinase (JAK) inhibitors have proven to be effective in several immune-mediated diseases. A deeper understanding of the pathomechanism of certain conditions continues to open up new indications for clinical practice. In the diseases-vitiligo and hidradenitis suppurativa- discussed in this publication, numerous clinical trials have evaluated their efficacy. Interestingly, in early-stages and limited cases, topical formulation instead of systemic administration appears to be promising. In the case of vitiligo, a topical JAK inhibitor has already been approved. In this publication, we summarize the ongoing studies for vitiligo and hidradenitis suppurativa.
No takes yet. Share an insight, caveat, or question.
Kovács et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Bőrgyógyászati és Venerológiai Szemle